CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 GlobeNewswire October 01, 2025 CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat […]